Clinic News

Latest in Cardiology

• IL-6, hs-CRP, LDL and Residual Risk in Contemporary Practice
  Are markers of inflammation, interleukin-6 (IL-6), and high-sensitivity C-reactive protein (hs-CRP), and low-density lipoprotein cholesterol (LDL) levels, associated with cardiovascular (CVD) events in high-risk patients on contemporary medical therapy for CVD? 
• Dapagliflozin in Patients With Heart Failure and Reduced Ejection Fraction
  The goal of the DAPA-HF trial was to evaluate dapagliflozin (a sodium-glucose cotransporter 2 [SGLT2] inhibitor) compared with placebo among patients with heart failure with reduced ejection fraction (HFrEF).
• Video: Day 1 Highlights | ACC.20/WCC Virtual
  Drs. Peter Block and Deepak Bhatt look back on Day 1 of ACC.20/WCC Virtual late-breaking science and featured clinical research, including VICTORIA (0:40), VOYAGER PAD (3:02), COMPASS Diabetes (6:50), and TAILOR PCI (12:15).
• Eagle's Eye View: Day 1 Highlights | ACC.20/WCC Virtual
  In this special episode of Eagle's Eye View, Dr. Peter Block and Dr. Deepak Bhatt discuss highlights from Day 1 of ACC.20/WCC Virtual, including VICTORIA, VOYAGER PAD, COMPASS Diabetes, and TAILOR PCI.
• Inclisiran for Heterozygous Familial Hypercholesterolemia
  The goal of the ORION-9 trial was to assess the safety and efficacy of inclisiran in lowering low-density lipoprotein cholesterol (LDL-C) among patients with heterozygous familial hypercholesterolemia (HeFH).  
• Impact of Inclisiran on LDL-C Over 18 months in Patients With ASCVD or Risk-Equivalent
  The goal of the ORION-11 trial was to evaluate inclisiran compared with placebo among patients with atherosclerotic cardiovascular disease (ASCVD) or ASCVD risk-equivalents. Inclisiran is a small interfering double-stranded RNA that inhibits PCSK9 production.
• Colchicine Cardiovascular Outcomes Trial
  The goal of the COLCOT trial was to evaluate colchicine compared with placebo administered within 30 days of a myocardial infarction.
• Cardiovascular Outcomes for People Using Anticoagulation Strategies
  The goal of the COMPASS trial was to evaluate anticoagulation strategies with rivaroxaban among patients with stable atherosclerosis.
• Inclisiran for Subjects With ASCVD and Elevated Low-Density Lipoprotein Cholesterol
  The goal of the ORION-10 trial was to evaluate inclisiran compared with placebo among patients with atherosclerotic cardiovascular disease (ASCVD). Inclisiran is a small interfering double-stranded RNA that inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9) production.
• COMPASS: Rivaroxaban Reduces CV Events in Atherosclerosis Patients With, Without Diabetes
  The combination of rivaroxaban plus aspirin may provide a similar benefit in reducing cardiovascular events in patients with stable atherosclerosis with and without diabetes, according to results of a substudy of the COMPASS trial presented March 28 at ACC.20/WCC during a Featured Clinical Research session and simultaneously published in Circulation.